文献速递乳腺癌放疗泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

2010至2020年单学术中心放射肿瘤治疗分次趋势

Trends in Radiation Oncology Treatment Fractionation at a Single Academic Center, 2010 to 2020.
PubMed 文献 · Adv Radiat Oncol · 2022-07-22

该研究从机构数据库提取2010至2020年全部癌症、乳腺癌、前列腺癌和骨转移四类病种的放疗记录,共22,865疗程、375,446次治疗,分析每疗程平均分次数逐年变化,并用分段线性回归评估COVID-19疫情是否与分次减少相关。结果显示全癌种每疗程平均分次数从2010年17.5次降至2020年13.6次,乳腺癌和前列腺癌的分次减少采用增加,骨转移在研究期前已基本采用大分割,多数病种的分次减少采用发生在疫情前。

要点

  • 全癌种每疗程平均分次数从2010年17.5次降至2020年13.6次。
  • 乳腺癌和前列腺癌的大分割采用增加;骨转移在研究期前已基本采用大分割。
  • 多数病种的大分割采用发生在COVID-19疫情前,仅骨转移不能排除疫情驱动增加。

核心结论

  • 研究期内多种癌症的大分割方案使用增加,且在该机构主要发生在COVID-19疫情前。
  • 仅骨转移不能排除疫情驱动的大分割采用增加。

研究设计与样本

  • 单学术中心机构数据库提取2010至2020年全部癌症、乳腺癌、前列腺癌和骨转移四类病种的放疗记录,共22,865疗程、375,446次治疗。
  • 按病种报告每年度每疗程平均分次数,并用分段线性回归模型估计每疗程月平均分次数时间趋势的变化点及是否与疫情开始重合。

主要发现

  • 全癌种每疗程平均分次数从2010年17.5次降至2020年13.6次。
  • 该机构全癌种以及乳腺癌和前列腺癌的大分割采用增加。
  • 骨转移的大分割在研究期前已基本采用。
  • 多数病种的大分割治疗疗程采用发生在疫情开始前。
  • 骨转移是唯一不能排除疫情驱动大分割采用增加的病种。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recent clinical trials suggest hypofractionated treatment regimens are appropriate for treatment of many cancers. It is important to understand and document hypofractionation adoption because of its implications for treatment center patient volumes. There is no recent U.S. study of trends in hypofractionation adoption that includes comparisons of multiple disease sites and data since the onset of COVID-19. In this context, this study describes trends in treatment fractionation at a single academic center from 2010 to 2020. METHODS AND MATERIALS: From an institutional database, records were extracted for treatment of 4 disease site categories: all cancers, breast cancer, prostate cancer, and bone metastases. For each disease site, the mean number of fractions per treatment course was reported for each year of the study period. To explore whether the COVID-19 pandemic was associated with increased hypofractionation adoption, piecewise linear regression models were used to estimate a changepoint in the time trend of mean monthly number of fractions per treatment course and to evaluate whether this changepoint coincided with pandemic onset. RESULTS: The data set included 22,865 courses of radiation treatment and 375,446 treatment fractions. The mean number of fractions per treatment course for all cancers declined from 17.5 in 2010 to 13.6 in 2020. There was increased adoption of hypofractionation at this institution for all cancers and specifically for both breast and prostate cancer. For bone metastases, hypofractionation had largely been adopted before the study period. For most disease sites, adoption of hypofractionated treatment courses occurred before pandemic onset. Bone metastases was the only disease site where a pandemic-driven increase in hypofractionation adoption could not be ruled out. CONCLUSIONS: This study reveals increasing use of hypofractionated regimens for a variety of cancers throughout the study period, which largely occurred before the onset of the COVID-19 pandemic at this institution.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Cher BAY, Dykstra M, Wang C, et al. Trends in Radiation Oncology Treatment Fractionation at a Single Academic Center, 2010 to 2020. Adv Radiat Oncol. 2022. PMID: 36072755. doi:10.1016/j.adro.2022.101032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。